Pharmacokinetics and expert systems as aids for risk assessment in reproductive toxicology. by Mattison, D R & Jelovsek, F R
EnvironmentalHealthPerspectives
Vol. 76, pp. 107-119, 1987
Pharmacokinetics and Expert Systems as
Aids for Risk Assessment in Reproductive
Toxicology
by Donald R. Mattison*t# and Frederick R. Jelovsek**
A minimal approach to risk assessment in reproductive toxicology involves four components: hazard
identification, hazard characterization, exposure characterization, and risk characterization. In practice,
risk assessment in reproductive toxicology has been reduced to arbitrary safety factors or mathematical
models of the dose-response relationship. These approaches obscure biological differences across species
rather than using this important andfrequently accessible information. Two approaches that are formally
capableofusingbiologicallyrelevant information (pharmacokinetics andexpertsystemshells) areexplored
as aids to risk assessment in reproductive toxicology.
Introduction
In spite of gaps in our knowledge of reproductive
vulnerability to xenobiotics across species (1), data and
theoretical approaches are available that would allow
more rational and consistent prediction of human re-
productive risk. In addition, in vivo and in vitro ex-
perimental models are available that allow refinement
of those predictions. This discussion will explore the
utility of pharmacokinetics and expert systems as sci-
entific and regulatory tools in reproductive risk assess-
ment.
Reproductive Risk Assessment
At the present time, risk assessment in reproductive
toxicology is conducted by mostregulatory agencies us-
ing safety factors, multiples of 10-1 used to adjust a
defined dose or no-observed-effect-level in an experi-
mental animal model to the permissible level for human
exposure (2) (Fig. 1). One example of recommended
safety factors for teratogenicity that uses this factor of
10 approach has been proposed by Wilson and modified
by Schardein (Table 1). This approach suggests that for
drugs with a high benefit-to-risk ratio, doses similar to
those producing teratogenicity or embryotoxicity may
be used ifclinically indicated. For food additives or pes-
ticides, a safety factor of 100, and for environmental
pollutants, a safety factor of 1000, is suggested.
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Although the safe level in this factor of 10 approach
is defined by exposure or use, it is independent ofspe-
cies differences in anatomy, physiology, pharmacology,
and toxicology. Even worse, a factor of 10 approach to
permissible human exposure is doomed to overregulate
xenobiotics that are false positives and allows excessive
human exposure to false negatives, adding to social
costs and impairing human reproductive health.
Available Data on Reproductive Hazards
In their review, Barlow and Sullivan (1) collected an-
imal and human data on 48 chemicals of industrial in-
terest (Table 2). All 48 chemicals had relevant phar-
macology and toxicology data, 38 were positive, pro-
ducing adverse effects in experimental animals, and 10
were negative. In no case were the data from experi-
mental animal studies insufficient for assigning the
chemical to a group, either positive or negative. In hu-
mans, there were sufficient pharmacologic and toxico-
logic data on only 19 of the 48 chemicals, all positive.
The remaining 29 studies had insufficient data concern-
ing human pharmacology and toxicity.
The authors then evaluated the available data from
animals and humans addressing reproductive toxicity;
endocrine or gonadal effects, alteration in fertility, and
effects on pregnancy.
Among the 48 chemicals, 11 had data suggesting ad-
verse gonadal effects in male or female experimental
animals, 4 were negative in males, and 2 were negative
in females. Most ofthe chemicals, however, had insuf-
ficient data to define gonadal toxicity in experimental
animals or humans. Xenobiotic effects on fertility were
also poorly characterized, with no animal data on 33 or
34 compounds, and insufficient human data on 45 or 46MATTISON AND JELOVSEK
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FIGURE 1. Current approach to risk assessment in reproductive
toxicology.
chemicals. Although there is a bit more data on the
effects of these 48 chemicals on pregnancy in experi-
mental animals, human data are clearly lacking.
This suggests two factors: For many chemicals, ani-
mal data necessary to define reproductive hazard are
not available, and where animaldataare available, even
minimal human data are lacking. Therefore, once a re-
productive hazard has been identified, extrapolation
across species will be necessary to define human risk.
Extrapolation Across Species
Thenecessitytodevelop bettermethods ofpredicting
human reproductive risk from animal data is illustrated
for teratogenicity (Table 3) (3). This table summarizes
a review conducted by Frankos ofxenobiotics classified
as human teratogens (38 drugs and chemicals) and 165
xenobiotics not hazardous during pregnancy (3). Note
that not all reproductive toxicologists would agree that
there are 38 known human teratogens; however, it is
instructive to examine the table for its meaning (see
Table 4 for a list of animal and human teratogens).
Table 1. Suggested safe levels of different chemicals with
teratogenic potential.a
Embryotoxicity/usage
Chemical class ratio
Drugs with high benefit/risk ratio 1:> 1
Drugs (general) 1:1 to 1:0.1
Food additives, pesticides 1:0.01
Air, water, and food pollutants 1:0.001
aFrom Schardein (2).
Table 2. Reproductive hazards of industrial chemicals.a
Endocrine
Pharmacology and gonadal Fertility
and toxicology M F M F Pregnancy
Animal
Positiveb 38 11 11 9 9 17
Negativec 10 4 2 6 5 9
No datad 0 33 35 33 34 22
Human
Positive 19 8 6 2 1 6
Negative 0 0 3 1 1 1
No data 29 40 39 45 46 41
aFrom Barlow and Sullivan (1).
'Positive, studies performed suggest toxicity.
'Negative, studies performed suggest no toxicity.
dNo data, no studies or inconclusive.
Table 3. Animal models as predictors of human teratogens.'
Mouse Rat Rabbit Hamster Monkey
Positive (38)b 85%+ 80%+ 60%+ 45%+ 30%+
Negative (165)C 35%- 50%- 70%- 35%- 80%-
aPositive and negative compounds not specified. From Frankos(3).
bPositive, reports ofbirth defects in humans.,
'Negative, known not to be human teratogens.
Ofthosexenobioticspositive forreproductivetoxicity
in humans, 85% were positive in the mouse, and 80%
were positive in the rat. In the rabbit, hamster, and
monkey, 60, 45, and 30% were positive, respectively.
The species with the best record in identifying human
teratogens, the mouse, was positive for 85% of xeno-
biotics thought to be human teratogens. Among those
xenobiotics that were not human teratogens, only 35%
were correspondingly negative in the mouse and the
hamster. In the rat, rabbit, and monkey, 50, 70, and
80% were negative, respectively. This disparity indi-
cates that it is essential to develop better predictors.
Mechanism-based physiological-pharmacokinetic
models and expert systems for defining human repro-
ductive risk appear appropriate.
Approach to Risk Assessment in
Reproductive Toxicology
Conducting risk analysis using safety factors does
provide a level for permissible human exposure; unfor-
tunately, this number cannot be adjusted by advances
in reproductive physiology, pharmacology, or toxicol-
ogy. In addition, using safety factors to set permissible
human exposures is unacceptable because the uncer-
tainty is completely undefined. A more rational ap-
proach for risk assessment would be to determine the
physiological, pharmacological, toxicological, cellular,
and molecular characteristics that control reproductive
toxicity in experimental models and translate that in-
formation into predicted human risk based on similar
human characteristics (Fig. 2).
Three specific areas need to be addressed to develop
risk assessment in reproductive toxicology. The first
area is gathering data on reproductive physiology and
the reproductive effects of a broad range of chemicals
across species. One component of this is development
ofdata bases that encourage efficient use ofpreviously
collected information on reproductive physiology, phar-
macology, and toxicology.
The second area of need is methods for translating
information on reproductive hazards in experimental
animals into risk assessments that protect human pop-
ulations.
Finally, the third area of need is experimental and
theoretical models that can define the site and mecha-
nism of action of reproductive toxins (4).
Teratogenicity Across Species
One of the major limitations in conducting risk as-
sessments in reproductive toxicology is the diversity of
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Table 4. In vivo teratology data: Comparison across species.a
Rule-based estimate ofrisk
Compound Mouse Rat Rabbit Monkey Human S SS P
Chloroambucil + + + H H H
Coumarin + + M L M
Cyclophosphamide + + + + + H H H
Diazepam + - + M M M
Diethylstilbestrol + + + + H H H
Diphenylhydantoin + + + + H H H
Ethanol + + + H H H
5-Fluorouracil + + + + H H H
Meprobamate + + - + H H H
Methotrexate + + + + + H H H
Methylmercury Cl + + + H H H
L-Phenylalanine + + M M H
Procarbazine HCl + + + + H H H
13-cis-Retinoic acid + + + H H H
Testosterone proprionate + + + H M H
Thalidomide - - + + + M M H
Acetylsalicylic acid + + + - H H H
Caffeine + + + - H H H
Diphenhydramine HCl - - - - L L L
Doxylamine succinate - - - - M L L
Isoniazide - - - - L L L
Penicillin G - - - M L M
Saccharin - - - - L L L
2,4,5-T + - - - M M M
Abbreviations: S, sum rules; SS, sum of square rules; P, primate rules; H, high risk for human teratogenicity; M, moderate risk for human
teratogenicity; L, low risk for human teratogenicity.
aData from Schardein (2), Frankos (3), Smith et al. (5), and Shepard (6).
reproductive physiology across species. This diversity
suggests that for extrapolation across species, risk as-
sessments require access to data detailing species dif-
ferences inreproductive physiology, pharmacology, and
toxicology (Table 4). Note that Table 4 lists only 16
compounds as positive human teratogens, fewer than
the 38 compounds indicated in Table 3. Among those 16
compounds thought to be human teratogens, 12 were
also teratogenic in all other species tested. Among the
8that arethoughtnottobeteratogenic, 5 werenegative
in all species tested. Discordance in the outcome across
species for agiven reproductive end point suggests that
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FIGURE 2. Suggested approach to reproductive risk assessment.
hazard identification, the first step in risk analysis, is
not a trivial process. Clearly, a more detailed analysis
of animal responses to reproductive toxins will be nec-
essary before quantitative risk assessment can be per-
formed. Our discussion of expert systems is designed
to explore one approach to this problem.
Because of past research interests in reproductive
medicine, a considerable amount of data are available
on maternal, placental, and fetal physiological param-
eters for humans, nonhuman primates, and sheep. In
addition, a large amount oftoxicological data exploring
embryonic and fetal effects ofxenobiotics are available
for rodents. This physiological, pharmacological, and
toxicological data should be collected into a computer-
ized data base and made available to interested inves-
tigators. To demonstrate the utility ofsuch a data base
we will also review the impact ofphysiological changes
during human pregnancy on xenobiotic uptake, distri-
bution, metabolism, and excretion.
Expert Systems
Physicians are frequently confronted with questions
concerning the effects of a drug or chemical on human
reproduction. As previously indicated (Table 2) there
are generally insufficient data to identify the drug or
chemical as a reproductive toxin for humans. For this
reason it is almost always necessary to extrapolate re-
productive toxicity data across species to arrive at a
prediction of the likelihood of human hazard and esti-
mate the degree of human risk.
EXPERIMENTATION
in vitro
in vivo
|PREDICTIVE MODELS
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Table 5. Structure of ESIE rule-based expert system shell.
Process Number allowed
Goal: Human teratogenicity 1
Legal answers: Yes, no, ? 50
Rules (See Table 7) 400
Questions 100
Answer: The risk for human teratogenicity is 1
Extrapolation across species to define human risk is
a difficult process that requires knowledge of species
differences inreproductive biology, development, phar-
macology, and toxicology, all highly specialized disci-
plines. Because of the complex nature of knowledge
required to make a rational judgment of human risk,
the utility of an expert system shell has been explored
for risk assessment in reproductive and developmental
toxicology.
Expert System Shell
The expert system shellused was ESIE (Expert Sys-
tem Inference Engine, Lightway Consultants, Tampa,
FL). ESIE is a rule-based expert system shell written
inPASCAL forMS-DOS computers. The expert system
shell is first given a goal; in this case the goal is to
determine the relative risk for human teratogenicity
(Table 5). The software then is given the allowable an-
swers (6 50) to the questions. In this example the al-
lowable answers to questions concerningteratogenicity
were: yes, the compound is teratogenic; no, the com-
pound does not produce teratogenicity; or ?, the tera-
togenicity ofthe compound is underfined eitherbecause
of the lack of data or the presence of confficting data.
The rules that determine how responses to questions
are treated are then defined. This expert system shell
is capable ofusing up to 400 rules.
The expert system shell can then be programmed to
request information by asking up to 100 questions. The
response to these questions must be in the format of a
legal answer (e.g., yes, no, ?). This information is then
interpreted with the rules.
Animal Data
Because of the limitation on the number of rules (s
400) that can be used in ESIE, it was decided to limit
the number of species of animals for which teratogen-
icity information was requested. In order to determine
which experimental animals would be useful to include
in the rules written for ESIE, a survey ofanimals used
in teratogenicity testing was conducted (Table 6) using
a recently published reference (2). According to Schar-
dein, approximately 1528drugs and 1252chemicals have
been evaluated for teratogenicity in experimental ani-
mals.
Among the 1528 drugs that have been tested for ter-
atogenicity, 1124 (74%) were tested in rats, 686 (45%)
were tested in mice, and 566 (37%) were tested in rab-
bits. Among the 1252 chemicals tested for teratogen-
Table 6. Teratogenicity testing in experimental animals.a
Drugs Chemicals
Species Number % Number %
Rat 1124 74 862 69
Mouse 686 45 435 35
Rabbit 566 37 196 16
Hamster 110 7 111 9
Dog 52 3 17 1
Pig 35 2 31 2
Sheep 33 2 39 3
Guinea pig 39 3 23 2
Cat 10 <1 5 <1
Ferret 8 <1 2 <1
Cow 13 < 1 33 3
Horse 2 <1 4 <1
Primate 82 5 24 2
Total 1528 1252
aThis table lists drugs and chemicals that have been studied for
teratogenicity. Note that some drugs or chemicals were tested in
more than one experimental animal model.
icity, 862 (69%) were tested in rats, 435 (35%) were
tested in mice, and 196 (16%) were tested in rabbits.
These data suggest that including rules concerning the
teratogenicity ofa compound in rats, mice, and rabbits
will include the experimental data available for many
compounds. In addition, based on cost and regulatory
considerations, there is little reason to think that the
use of these species for teratogenicity testing will
change in the near future.
Expert System Rules
The rules used in this expert system are shown in
Table 7. The rules and their corresponding questions
are closely linked. The three questions asked are: Is the
compound teratogenic in rats? Is the compound tera-
togenic in mice? and Is the compound teratogenic in
rabbits?
The difficult part ofthis expert system, as indeed the
most complex part of any expert system, is actually
defining the rules. That is, how should a given set of
animal outcomes be evaluated with respect to human
hazard? In this implementation of the expert system,
information was requested by questions on the terato-
genicity in three species: rat, mouse, and rabbit. Ifthe
compound had been tested and was known to be posi-
tive, that is, ifit produces malformations or fetal death
at doses below those associated with maternal toxicity,
the answer is "yes," ifnegative, the answer is "no." If,
however, the compound had not been tested, or if the
data were difficult to interpret or contradictory, the
answer is "?".
Thereare27differentcombinationsoftheseallowable
answers among the three species (Table 7). Two ways
were initially used to define the human teratogenicity
ofa given combination. In both cases the allowable an-
swers were given a numerical score: no = 1, ? = 2, yes
= 3. In the first method (sum rule) the answers were
summed and the human risk determined as defined on
Table8. Asecondrulewasalsoexplored-thenumerical
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Table 7. Rules used in expert systems for teratogenicity.
Mouse
No(1)
No(1)
No(1)
No(1)
No(1)
No(1)
No(l)
No(1)
No(1)
?(2)
?(2)
?(2)
?(2)
?(2)
?(2)
?(2)
?(2)
?(2)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Yes(3)
Rat
No(1)
No(1)
No(1)
?(2)
?(2)
?(2)
Yes(3)
Yes(3)
Yes(3)
No(1)
No(1)
No(1)
?(2)
?(2)
?(2)
Yes(3)
Yes(3)
Yes(3)
No(1)
No(1)
No(1)
?(2)
?(2)
?(2)
Yes(3)
Yes(3)
Yes(3)
Rabbit
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
No(1)
?(2)
Yes(3)
Sum
3
4
5
4
5
6
5
6
7
4
5
6
5
6
7
6
7
8
5
6
7
6
7
8
7
8
9
Sum of
squares
3
6
11
6
9
14
11
14
19
6
9
14
9
12
17
14
17
22
11
14
19
14
17
22
19
22
27
Table 8. Sum rules for predicting human teratogenicity using
mouse, rat, and rabbit data.
Sum Human teratogenic risk
3 Low
4 to 6 Moderate
7 to 9 High
Table 9. Sum of squares rule for predicting human
teratogenicity using mouse, rat, and rabbit data.
Sum of squares Human teratogenic risk
--6 Low
>6 to < 19 Moderate
: 19 High
scores were squared before summing. This second ap-
proach has the advantage ofweighing positive and un-
certain data more than negative data. Using the sum
of squares method, human risk for teratogenicity was
determined as defined on Table 9.
In addition, a third set of rules was derived by in-
cluding data on teratogenicity testing in nonhuman pri-
mates. The structure ofthis third set ofrules was sim-
ilar to the sum of squares rules with the exception that
teratogenicity in a nonhuman primate was considered
to represent high teratogenic risk for humans.
Testing the Rules with Human and Animal
Data
Using the three sets ofrules, it is possible to explore
predictability using compounds defined as teratogenic
or nonteratogenic in humans (Table 4). The results of
using these three sets of rules to evaluate human ter-
atogenic risk with these data are illustrated in Table
10.
Using the sum rule, 12 ofthe 16 compounds that are
teratogenic in humans were identified as having high
teratogenic risk. The remaining 4 ofthe 16 were class-
ified as moderate human teratogenic risks. The sum of
squares rule classified 11 of 16 as high human terato-
genic risk among those identified as human teratogens.
Four were classified as posing moderate risk and one
as low human teratogenic risk. The third rule set using
primate data classified 14 of 16 as representing high
human teratogenic risk and 2 as moderate teratogenic
risk.
Finally, among the 8 compounds identified as non-
teratogenic for humans, the sum, sum of squares, and
primate rules classified 2 as high risk. Three were class-
ified as moderate risk using the sum, 2 using the pri-
mate, and 1 using the sum of squares rule. The classi-
fication of low risk was applied to 3 compounds using
the sum, 5 using the sum of squares, and 4 using the
primate rules.
More complex rules containinginformation on testing
in other species, dose-response relationships, and types
ofmalformations can be developed and evaluated inthis
and other expert system shells. The utility of this ap-
proach is the consistent definition of reproductive haz-
ard. Wherehuman experts disagree onthe classification
ofa compound, the disagreement can be used to design
experimentsthatenhance therulesused inthe decision-
making process. Note that these rule-based expert sys-
tems will initially have greatest utility in hazard iden-
tification and qualitative risk assessment. Quantitative
risk assessment will need to be based on physiological
and pharmacokinetic models.
Maternal Physiological Alterations
During Pregnancy
Complex alterations in maternal pulmonary, cardio-
vascular, renal, gastrointestinal, and hepatic function
occur during pregnancy (7,8). These physiological
changes during pregnancy may alter the uptake, dis-
tribution, metabolism, orclearance ofxenobioticsbythe
pregnant woman, placenta, and fetus (9-12). Physiolog-
ical alterations during pregnancy may also alter mater-
nal response to environmental toxins. Any method for
quantitative riskassessmentthatincludesextrapolation
across treatment, route, or species for maternal, pla-
cental, or fetal toxicity must consider these physiolog-
ical adaptations.
Absorption
During pregnancy there are physiological changes in
several systems that can alter the rate and amount of
a xenobiotic absorbed. Intestinal motility is decreased
and gastric emptying time is increased during preg-
nancy (13). This means that xenobiotics will spend a
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Table 10. Prediction of human teratogenic risk using an expert system shell.
Expert system rule
Sum Sum of squares Primate teratogenicity
Human teratogenicity High Moderate Low High Moderate Low High Moderate Low
Teratogenic 12 4 0 11 4 1 14 2 0
Nonteratogenic 2 3 3 2 1 5 2 2 4
longer time in both the stomach and the small intestine.
Ifthexenobioticisabsorbedthroughthesmallintestine,
increased residence time in the stomach may delay the
time to peak concentration in maternal and fetal com-
partments. In addition, the xenobiotic may be metab-
olized in the stomach so that increased residence time
will decrease the amount ofparent compound available
for absorption. If the ingested xenobiotic passes
through the stomach unaltered, the longer time in the
small intestine may increase the fraction absorbed.
Pulmonary function also changes significantly during
pregnancy. Although the respiratory rate is unchanged
(14), the tidal volume, the volume of air per breath, is
increased from 487 to 678 mL (Table 11).
This means that the amount of a xenobiotic inhaled
is increased duringpregnancy. Forexample, ifthework
environment contains arsenic at a concentration of 0.2
mg/M2, a nonpregnant woman will inhale 0.72 mg in an
8-hr working day. Duringpregnancy, that same woman
will inhale 1.01 mg arsenic in the course of an 8-hr day
(Table 12). Similar increases in pulmonary dose ofben-
zene, ethylene oxide, and otherairbornexenobioticswill
occur during pregnancy.
It is not known ifthis change in pulmonary dose dur-
ing pregnancy is responsible for increased maternal or
fetaltoxicity; however, arecentstudy(15) suggeststhat
women are more vulnerable to silicosis than men. In
this study there was a significant gender difference in
the amount of time from the onset of exposure to di-
agnosis of silicosis. The mean duration of exposure to
diagnosis was significantly (p < 0.001) shorter for
Table 11. Pulmonary function changes during pregnancy.a
Function Nonpregnant Pregnant Change, %
Respiratory rate 15 16
Tidal volume, 487 678 +39
mL/min
Minute ventilation, 7,270 10,340 +42
mL
Minute 02 uptake 201 266 +32
Vital capacity, mL 3,260 3,310 +1
aData from deSwiet (14).
Table 12. Pulmonary dose of selected xenobiotics during
pregnancy.
Xenobiotic Nonpregnant, mg Pregnant, mg
Arsenic, 0.2 mg/m3 0.7 1.0
Benzene, 31 mg/m3 116.0 162.0
Ethylene oxide, 324.0 454.0
90 mg/im
women (20.5 ± 8.6 years), than for men (28.1 ± 10.1
years). The authors do not comment on the number of
pregnancies or on the duration ofwork exposure during
pregnancy. If these women worked during pregnancy,
however, they would be inhaling greater doses ofdust.
Interestingly, this phenomenon of shorter latency to
onset ofpulmonary disease in women has also been ob-
served in the German fire clay industry (15).
There are also substantial changes in blood flow to
different regions of the body during pregnancy. Blood
flow to the hand increases approximately sixfold during
pregnancy from 3 to 18 mL/min/100 mL tissue (16).
Blood flowto the foot doubles duringgestation, increas-
ingfrom 2.5 to 4 mL/min/100 mL tissue. Overthis same
period of gestation there are only small increases in
blood flow to the forearm and leg. The increase in blood
flow to the hand may have a significant impact on the
amount of xenobiotic absorbed.
Distribution
During pregnancy there are changes in body weight,
totalbody water, plasmaproteins, bodyfat, and cardiac
output that can alter the distribution ofxenobiotics (7-
9). Maternal cardiac output increases 40 to 50% by the
middle of the second trimester and remains elevated
throughout gestation (16). Maternal weight increases
from 50 kg at the start of pregnancy to 63 kg at 40
weeks (17). Totalbody waterincreases from25 L atthe
start of pregnancy to 33 L at term. Maternal extracel-
lular fluid volume increases from 11 L to 15 L over the
course ofpregnancy. Plasma volume increases from 2.5
to 3.8 L over the 40 weeks of gestation.
Maternal body fat also increases about 25% during
gestation (17). At the beginning of pregnancy the ma-
ternal body contains approximately 16.5 kg adipose tis-
sue. At 20 weeks of gestation maternal body fat has
increased to 18.5 kg, and by 30 weeks to 20 kg. This
increase in body fat during pregnancy will increase the
body burden of lipid-soluble xenobiotics during preg-
nancy, and may have an impact on the delivery of xe-
nobiotics to the infant through the placenta and lacta-
tion.
The increase in plasma volume and total body water
during pregnancy may decrease the concentration of
some xenobiotics in maternal and fetal compartments.
For example, if the volume of distribution in the non-
pregnant woman is 5 L and if 50% of a xenobiotic (100
mg exposure) is absorbed, the initial concentration will
be 10 mg/L. Suppose that duringpregnancythe volume
of distribution increases to 6, 7, and 8 L at 20, 30, and
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40 weeks. This increase in volume of distribution will
decrease the concentration of the absorbed xenobiotic
to 8.3, 7.1, and 6.3 mg/L at 20, 30, and 40 weeks of
gestation. Therefore, maternal sensitivity for some xe-
nobiotics may decrease during pregnancy.
Metabolism
The altered hormonal milieu of pregnancy is associ-
ated with changes in hepatic and extrahepatic metab-
olism of xenobiotics (11,12). In addition, during gesta-
tion, metabolism by the fetus and placenta may alter
maternal levels of the parent xenobiotic or its metab-
olites(10). Placentalandfetalmetabolismofaxenobiotic
may also influence fetal or placental toxicity.
Using classical pharmacokinetics, Gillette (10) has
evaluated the impact of fetal metabolism on maternal
and fetal levels ofhypothetical xenobiotics. He suggests
that fetal metabolism has only a small effect on the
maternal concentration ofalipid-soluble xenobiotic that
is rapidly transported into the fetal compartment; how-
ever, fetal metabolism may lower the fetal concentra-
tion by half for rapidly transported lipid-soluble xeno-
biotics. If the xenobiotic is slowly transported to the
fetus, metabolism in fetal tissues may have an even
greater impact on fetal concentration. With a slower
rate oftransport to the fetus, metabolism reduces fetal
concentrations to 20% of the concentration if fetal me-
tabolism does not occur. Placental metabolism may also
play a similar role in altering maternal and fetal con-
centration of some xenobiotics.
Elimination
During gestation, alterations in renal blood flow, glo-
merularfiltration rate, hepaticblood flow, bileflow, and
pulmonary function may altermaternal xenobiotic elim-
ination (7-9). Duringpregnancy, maternal renalplasma
flow increases from 500 mL/min/1.73 m2 to approxi-
mately 700 mL/min/1.73 M2. Glomerular filtration rate
also increases during pregnancy. At the beginning of
gestation, glomerular filtration rate is approximately
100 mL/min/1.73 M2. By midgestation (20 weeks) the
glomerular filtration rate has increased to approxi-
mately 150 mL/min/1.73 m2.
Both increased renal plasma flow and glomerular fil-
tration rate will increase the elimination rate constant
for xenobiotics cleared by the kidney. If, for example,
the rate constant for elimination is 0.5 min-1 at the
beginning of gestation and increases to 0.7 min -1 at
midgestation and 0.9 min-1 at term, the xenobiotic will
be cleared more rapidly during pregnancy. Note that
use ofphysiological models will directly account for this
change in elimination by increased renal blood flow
(18,19).
Consider, for example, a xenobiotic whose volume of
distributionincreasesproportionally tomaternalweight
during pregnancy, and whose rate of elimination also
increasesfrom0.10to0.15min-1duringthefirsttrimes-
ter. As pregnancy advances, the increased volume of
distribution decreases the initial concentration of the
xenobiotic in maternal plasma. The increase in elimi-
nation rate constant increases the rate at which the
xenobiotic is cleared from the body. This suggests,
again, that for some xenobiotics, maternal tolerance
may actually increase during pregnancy; however, in-
creased renal clearance during pregnancy may, by in-
creasing the dose ofxenobiotic delivered, increase tox-
icity to the maternal bladder epithelium.
Placenta
Following implantation in the primate, the placenta
begins to exert control on the maternal organism. The
first signal sent by the placenta, human chorionic go-
nadotropin (hCG), stimulates continued ovarian pro-
duction of progesterone. In the absence of hCG pro-
duction, or in the face ofovarian inability to respond to
hCG, spontaneous abortion will occur. During implan-
tation, therefore, the success ofpregnancy depends on
interactions between the ovary and placenta. Following
establishment, the placenta will determine the success
ofthe pregnancy. In other species, however, the ovary
plays amore prominent role in themaintenance ofpreg-
nancy throughout its entire course (20).
During implantation, the placenta invades the endo-
metrium, which formed under hormonal control of the
ovary, and maternal and fetal circulatory systems are
created. In primates, the maternal portion of the pla-
centa, the lobules, are poorly defined regions separated
by incomplete septa. The fetal portion of the primate
placenta, cotyledons, are discrete entities. There are
generally several cotyledons within each lobule. The
gross and microscopic structure of the placenta is
strongly dependent on the species, however, so this
description ofthe primate placenta will notbe adequate
for many experimental animals (Table 13).
Exchange of proteins, amino acids, carbohydrates,
fats, gases, and xenobiotics between the maternal and
fetal circulatory systems occurs across the placenta.
Quantitative risk assessment for teratogenicity or fetal
toxicity must consider species differences in placental
type and structure (Table 13). In addition, quantitative
risk estimation must consider differences in placental
surface area during pregnancy (Table 14), as well as
differences in fetal ormaternalblood flowratesthrough
their respective circulatory units in the placenta.
Across species, for example, there are substantial
differences in placental type that may explain some of
the differences in response to teratogens. Rats have
only a single layer offetal cells separatingthe maternal
circulation from the fetal circulation. In humans there
are three layers separating maternal and fetal circula-
tory systems in the mature placenta and four layers in
the first trimester placenta. This difference may, in
part, account forthe high false positive rate seen in the
rodent (Table 3). The use of mechanism-based physio-
logical-pharmacokinetic models, however, may allow
those differences to be considered in defining human
reproductive hazard and risk assessments.
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Table 13. Tissue layers separating maternal and fetal circulations.
Maternal tissue Fetal tissue
Placental type Epithelium Connective tissue Endothelium Trophoblast Connective tissue Endothelium
Epitheliochorial
Pig + + + + + +
Horse + + + + + +
Donkey + + + + + +
Syndesmochorial
Sheep + + + + + +
Goat + + + + + +
Cow + + + + + +
Endotheliochorial
Cat + + + +
Dog + + + +
Ferret + + + +
Hemochorial
Man + + +
Monkey + + +
Hemoendothelial
Guinea pig +
Rat +
Table 14. Surface area of the human placenta during gestation.
Gestation, days Surface area, m
100 1.5
120 2.5
170 4.7
190 4.9
220 7.3
240 14.0
270 (term) 15.0
Comparative surface area across species and during
gestation also needs to be considered in formulating a
rational risk assessment. For example, in the human
the placental surface area increases from about 1.5 m2
at 100 days gestation, to 15 m2 at term (Table 14). It is
clear that comparative transfer rates, taking into con-
sideration number oftissue layers, distance separating
circulations, and placental area must be considered in
any quantitative risk assessment exploring embryonic
or fetal toxicity. Those deficits represent significant in-
formation gaps in the pharmacokinetic models that can
be addressed by physiological models.
Definingthe effectofanychemical onthefetus, either
directly or indirectly, requires elucidation of placental
metabolism and transfer. At the present time, research
usinghuman fetal tissues from first or second trimester
pregnancies is quite difficult for ethical, legal, and pro-
ceduralfactors. Forthat reason mostresearchhasbeen
restricted to definingplacental transfer and metabolism
using term human placenta. It is hoped that with the
easingoftheserestrictions, andwithgreaterexperience
in defining placental function with termplacenta, it will
be possible to characterize placental function (transport
and metabolism) in second and first trimester placenta.
In the interim, it will be possible to approach many of
these questions using animal models.
By the third trimester much of the structure of the
fetus has been defined, but during this period, many of
the functional characteristics ofthe fetus are being de-
veloped. For example, cellular communication (e.g.,
neuronalcontacts)isbeingdeveloped, asisthecellnum-
ber in many organ systems. In addition, the fetus re-
mains vulnerable to cytotoxic or disruptive processes
during the third trimester. Finally, during the third
trimester, issues offetal effects from environmental ex-
posure remains a substantial concern.
Existing evidence suggests that placental transfer
from maternal to fetal circulatory system occurs for
essentially every compound tested. Placental metabo-
lism is less likely, although it has been demonstrated
forselected compounds (21-23). When placental metab-
olism does occur, it may have a significant impact on
fetal concentrations and fetal or placental toxicity. In
addition to mediating fetal toxicity by transferring the
parent compound or metabolites into the fetal circula-
tory system, placental toxicity by destruction of pla-
cental cells or placental functions may have similar dis-
ruptive effects on the fetus. For example, in experi-
mental animals prenatalexposure to cadmium produces
fetal death. This effect is not the result of direct fetal
toxicity, but is the result ofplacental toxicity. For that
reason, xenobiotic uptake and effect on placental func-
tion are as important as placental transport ofthe par-
ent xenobiotic or metabolism and transport of metab-
olites to the fetus.
Physiological and Pharmacokinetic
Models
Models of many types are used in all phases of bio-
logical research (4). The models are simplified rules or
systemsusedtoorganizeourviewofbiologicalstructure
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and function. In both an experimental and theoretical
sense, models are used to define and predict the re-
sponses of complex organisms or organ systems to ex-
ternal forces or factors. This portion of the paper will
explore pharmacokinetic models that can be used to
predict human risk for adverse reproductive outcome
following xenobiotic exposure.
Classical pharmacokinetic models begin with com-
partmental descriptions ofthe structure ofinterest. Al-
though they are of value in many situations, these
models may be limited in defining target tissue dose of
a compound. In addition, classical compartmental phar-
macokinetic models do not provide a direct approach to
account continuously for alterations in physiology,
growth, ordevelopment. As such, these compartmental
models represent static images ofthe system at a par-
ticular time or stage of development. This should not
be interpreted as suggesting that pharmacokinetic
models are of little value. On the contrary, classical
pharmacokinetic models can be, and have been, used to
provide insight into the effects ofhormonal alterations,
placental function, physiological changes during preg-
nancy, growth, and development on xenobiotic pro-
cessing and toxicity.
Physiological models represent a different approach
to the formulation of a quantitative model. This ap-
proach is appealing to many biologists because phys-
iological models retain biological, physiological, and an-
atomicalinformation as discrete parameters that can be
modified. The ability to modify the parameters of the
model is especially appealing for biologists exploring
reproductive processes with changing characteristics,
including vulnerability. Physiological models are also
appealing to toxicologists because they allow a direct
approach for the evaluation oftarget tissue toxicity and
metabolic cooperation between organs (e.g., maternal
liver-placenta-fetal liver).
Fetal and Maternal Organisms: Three-
Compartment Models
Having explored some of the physiological changes
that occurduring pregnancy, itisinstructive toconsider
the effects ofthese changes on the amount and concen-
tration of a xenobiotic in maternal and fetal compart-
ments (Fig. 3). The three-compartment model used is
composed ofmaternal central, maternal peripheral, and
fetal tissues (24,25). Xenobiotic elimination may occur
through maternal or fetal compartments; however, in
these simulations we will only consider elimination
through the maternal central compartment. Exchange
betweenmaternal andfetalcompartments occurs across
the placenta, which changes considerably during ges-
tation (Table 14).
Inthesesimulations, therateofabsorption(doserate)
will be determined by blood flow to the hand (Table 15).
Volumes of distribution in the maternal and fetal com-
partments will be defined by maternal plasma volume,
extravascular fluid volume, and fetal weights, respec-
tively (Table 16). The rate of elimination from the ma-
FIGURE 3. Three-compartmentpharmacokineticmodelduringpreg-
nancy. Parameter identification and assumptions used in this
model are: Vl = MC = plasma volume = maternal central com-
partment; V2 = MP = extravascular volume = maternal pe-
ripheral compartment; V3 = F = 0.8 x fetal weight = fetal
compartment; Klo = proportional to glomerular filtration rate;
K12 = constant; K13 = proportional to placental surface area; K20
= (30 = 0. Transfer between compartments is by diffusion.
Table 15. Parameters used in three-compartment
pharmacokinetic model of pregnancy: Absorption.
Hand blood flow,
Gestation, weeks mL/min/100 mL tissue
0 3.0
10 4.5 (1.5)a
20 6.0 (2.0)
30 12.0 (4.0)
40 18.0 (6.0)
aValues in parentheses indicate fold increase in the parameter.
Table 16. Parameters used in three-compartment
pharmacokinetic model of pregnancy: Distribution.'
Gestation, Maternal, L
weeks Central Peripheral Fetal, L
0 2.5 22
10 2.8 (1.1) 23 (1.05) 0.01
20 3.0 (1.2) 24 (1.09) 0.25 (25)
30 3.6 (1.4) 25 (1.14) 1.10 (110)
40 3.8 (1.5) 29 (2.80) 2.80 (280)
aMaternal central compartment is the plasma volume. Maternal
peripheral compartment is the volume of extravascular water. The
fetal volume of distribution is 80% of the fetal body weight. Values
inparentheses representthefold increase ofthe indicated parameter.
Table 17. Parameters used in three-compartment
pharmacokinetic model of pregnancy: Rate constants.
Gestation, Renal plasma flow, Placental surface
weeks mL/min/1.73 m2 area, m2
0 500
10 760 (1.5)a 1.0
20 760 (1.5) 3.0 (3)
30 680 (1.4) 7.3 (7.3)
40 720 (1.4) 15.0 (15.0)
aValues in parentheses indicate the fold increase ofthe parameter.
ternal compartment willbeproportionaltorenalplasma
flow (Table 17). The rate of transfer of xenobiotics be-
tween the maternal and fetal compartment will be pro-
portional to placental surface area (Tables 14 and 17).
Note that these simulations are by no means the only
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ones that could have been performed. For example, it
is possible to explore altered absorption in pregnancy
through pulmonary function, ingestion, or transport,
which is dependent on placental weight ratherthan sur-
face area.
Xenobiotic Absorption Through Hand
Epithelium
During pregnancy, blood flow to the hand increases
approximately sixfold. If the hand is the major site of
xenobiotic absorption, there will be a sixfold increase
in the rate of dosing (Table 18). In this simulation, the
maternal central compartment (MC) is the plasma vol-
ume, the maternal peripheral compartment (MP) is the
extravascular volume, and the fetal compartment (F) is
proportional to fetal body water (0.8 x fetal body
weight). Elimination from the central compartment
(Klo) occurs via the kidney and is proportional to glo-
merular filtration rate. Transfer from maternal central
to the peripheral compartment (K12) is constant
throughout pregnancy. Transferfromthe maternal cen-
tral to fetal compartment (K13) is proportional to the
placental surface area. Elimination does not occur from
either maternal peripheral or fetal compartments and
transfer between compartments occurs by diffusion. To
make the simulation somewhat more realistic, we will
assume that exposure occurs only from 8:00 A.M. to
12:00 noon and again from 1:00 P.M. to 5:00 P.M., on
weekdays (Table 19). Figure 4 illustrates typical daily
and weekly exposure simulations for a nonpregnant
woman.
In the one-day simulation, the initial concentration of
the xenobiotic is zero because it is assumed that this
will be the first day of exposure, on the job. Exposure
then begins at 8:00 A.M. and continues until noon, when
the lunch break is taken. During the lunch break the
concentration in the maternal central compartment
falls; little change is noted in the maternal peripheral
compartment. The fetal compartment is not shown be-
cause the woman is not pregnant (Fig. 4) (Table 20).
The one-weeksimulation is theremainderofthe week
for this particular nonpregnant woman (Fig. 4). At the
end of the first work day, the concentration falls over
the evening, throughout the night, and begins to in-
crease again on the morning of the second day. Ulti-
mately, by Friday at 5:00 P.M., the maximum concen-
tration is achieved in the maternal compartment (Fig.
4) (Table 21). Over the weekend the concentration of
the xenobiotic falls in the maternal central and periph-
eral compartments; however, the rate ofdecline is very
slow. At the beginning of the second week of work,
therefore, the concentration in the maternal compart-
ments is quite high and will continue to rise over suc-
ceeding weeks of exposure.
In performing these simulations in nonpregnant
women and at 10, 20, 30, and 40 weeks ofgestation, we
have used two assumptions: first, that the increase in
blood flow to the hand has no effect on xenobiotic ab-
sorption, and second, that the only significant altera-
tions are those occurring to the maternal organism (Ta-
bles 16-18). The simulations with constantmaternal ex-
posure are shown on Figures 5 and 6 (A,C,E,G). The
simulations with increasing maternal absorption (dose)
are also shown on Figures 5 and 6 (B,D,F,H).
Ifmaternal absorption does notincrease during preg-
nancy, then the concentration in the maternal central
compartment atthe end ofthe workdayfalls from2.072
prior to pregnancy to 1.042 at the end ofthe pregnancy
(Fig. 5) (Table 20). Similarly, the concentration at the
end of the work day in the maternal peripheral com-
partment falls from 0.116 prior to pregnancy to 0.069
at the end of pregnancy. Because of changes in the
maternal organism over pregnancy with a fixed absorp-
tion, the concentration also falls in the fetal compart-
ment at the end ofthe work day from 1.755 at 10 weeks
to 0.620 at term. Note that during the evening the con-
centration increases inthematernalperipheraland fetal
compartments, but that these concentrations also de-
crease over gestation. A similar decrease in the con-
centration of xenobiotic in the maternal central, pe-
ripheral, and fetal compartments will also be observed
over the work week with constant maternal absorption
during pregnancy (Fig. 6A,C,E,G) (Table 21).
If the increase in blood flow to the skin produces a
similar increase in absorption, there will be an increase
in the concentration in the maternal central, maternal
peripheral, and fetal compartments over the course of
gestation (Fig. 5B,D,F,H) (Table 20). For example,
with increasing exposure, the concentration of xeno-
biotic in the maternal compartment at the end ofawork
day will increase from 2.072 to 6.25 at term, approxi-
mately a threefold increase compared to the pregnant
constant exposure at term. The sixfold increase, con-
Table 18. Maternal and fetal concentrations: Absorption proportional to maternal hand blood flow.
Gestation, Volumes, L Rate constants, hr-1
weeks Dose, Fdhra MC MP F k1o k12 k13
0 1.0/- 2.5 22 0.010 0.1 0.
10 1.0/1.5 2.8 23 0.01 0.015 0.1 0.01
20 1.0/2.0 3.0 24 0.25 0.015 0.1 0.03
30 1.0/4.0 3.6 25 1.0 0.014 0.1 0.07
40 1.0/6.0 3.8 29 2.8 0.014 0.1 0.15
Abbreviations: MC, maternal central compartment; MP, maternal peripheral compartment; F, fetal compartment.
aExposure occurs from 8:00 A.M. to 12 noon and from 1:00 P.M. to 5:00 P.M., 5 days a week. The dose rate on the left represents unchanged
absorption during pregnancy that on the right represents a dose proportional to blood flow in the hand.
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Table 19. Maternal and fetal concentrations: Maternal hand
blood flow.
Exposure schedule
Day 1 Day2 Day3 Day4 Day 5
8 Ra 8 R 8 R 8 R 8 R
12 Ob 12 0 12 0 12 0 12 0
1 R 1 R 1 R 1 R 1 R
5 0 5 0 5 0 5 0 5 0
aR, Occupational exposure period.
b0, Time at which occupational exposure stops.
DAY EXPOSURE WEEK EXPOSURE
3
2 \Mc
1 M
0
0 4 8 12 16 20 24 0 24 48 72 96 120 144 168
Time (hrs)
FIGURE 4. Simulations of maternal central (MC) and maternal pe-
ripheral (MP) concentrations of a xenobiotic absorbed through
hand epithelium in an occupational setting for a nonpregnant
woman. Exposure and absorption only occurs between 8:00 A.M.
to 12 noon and 1:00 P.M. to 5:00 P.M. Left: 1-day exposure. Right:
5-day exposure.
sistent with the increase in blood flow to the skin, will
be reflected in a similar increase in the concentrations
ofthe maternal peripheral and fetal compartments.
In the one-day simulations, the maximum concentra-
tioninthematernalcompartmentwili occurat5:00 P.M.,
the end of the exposure period (Table 20) (Fig. 4 and
5). With fixed exposure over the course of gestation,
the xenobiotic concentration in the maternal central
compartment will decrease from2.072 to 1.042 ,/L from
the nonpregnant state until term, 40 weeks gestation,
(Fig. 5). Maternal peripheral concentrations will be
about 10% ofthose inthe centralcompartment, whereas
fetal concentrations will be quite close to those in the
maternal central compartment at 10 weeks. Over the
course of pregnancy, however, the fetal concentration
willdecline more thanthe maternal concentrations. The
greatest concentrations in the fetal compartment will
therefore be achieved early in pregnancy. As expected,
increasing exposure increases the xenobiotic concentra-
tion in the maternal central, maternal peripheral, and
fetal compartments; however, the increased concentra-
tion is less than the sixfold increase in blood flow. This
is due tothe parallelincrease involumes ofdistribution.
Similar changes in xenobiotic concentration are noted
at the end ofthe work week (Table 21).
In these simulations, ifabsorption is not altered dur-
ingpregnancy, the maternal organism is exposed to the
highest concentrations of the xenobiotic in the non-
pregnant state, and fetal concentrations are highest
during the first trimester, falling as pregnancy ad-
vances. This suggests that for some compounds, ma-
ternal toxicity mayactuallydecrease duringpregnancy.
Ifabsorption increases during pregnancy, then the ma-
ternal central, peripheral, and fetal concentrations will
increase during pregnancy. With increasing maternal
absorption, the likelihood of maternal toxicity will in-
crease during pregnancy as will the risk for fetal tox-
icity.
Conclusions and Recommendations
This is an exciting eraforresearch inrisk assessment
in reproductive toxicology. A range ofin vitro, in vivo,
and theoretical models are being explored that offer
promise for understanding normal and pathological re-
production and development. These models also offer
toxicologists the opportunity to define common links
between species forthe formulation ofrisk assessments
with well-characterized uncertainty.
The development of risk assessment in reproductive
and developmental toxicology across species, however,
will not come without research initiatives in several
areas. The areas that are most likely to be productive
include: establishment of a data base in reproductive
pharmacology, toxicology, andphysiology; development
ofpharmacokinetic and physiological models; validation
of the physiological and pharmacokinetic models with
Table 20. Concentration at the end of a single work day: Absorption proportional to blood flow to the hand epithelium.
Gestation, Fixed exposure Increasing exposure
weeks MC MP F MC MP F
0 2.072 0.116 -
(0.221)a () () () ()
10 1.814 0.109 1.755 2.721 0.164 2.633
(0.205) (1.755) (0.307) (2.633)
20 1.632 0.101 1.210 3.263 0.202 2.420
(0.189) (1.329) (0.378) (2.659)
30 1.262 0.090 0.788 5.049 0.361 3.151
(0.166) (0.912) (0.664) (3.650)
40 1.042 0.069 0.620 6.250 0.416 3.720
(0.125) (0.717) (0.750) (4.300)
aNumbers in parentheses represent the maximum concentration reached in the maternal peripheral or fetal compartments.
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Table 21. Concentration at the end of a work week: Absorption proportional to blood flow to hand epithelium.
Gestation, Fixed exposure Increasingexposure
weeks MC MP F MC MP F
0 2.926 1.123
(1.264)a () ( ) ()
10 2.535 1.005 2.473 3.802 1.507 3.710
(1.120) (2.473) (1.680) (3.710)
20 2.336 0.949 1.954 4.672 1.897 3.910
(1.059) (2.055) (2.119) (4.110)
30 1.970 0.875 1.586 7.881 3.501 6.346
(0.980) (1.678) (3.919) (6.712)
40 1.688 0.721 1.335 10.126 4.325 8.011
(0.820) (1.403) (4.920) (8.418)
aNumbers in parentheses represent the maximum concentration reached in the maternal peripheral or fetal compartments.
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FIGURE 5. Simulations of maternal central (MC), maternal periph-
eral (MP), and fetal (F) concentrations of a xenobiotic absorbed
through hand epithelium during the first day of occupational ex-
posure at 10 (A,B), 20 (C,D), 30 (E,F), and 40 (G,H) weeks of
gestation. Simulations with constant absorption through the hand
during pregnancy are illustrated by panels on the left. Simulation
withincreasingabsorption through the hand during pregnancy are
illustrated on the right.
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FIGURE 6. Simulations of maternal central (MC), maternal periph-
eral (MP), and fetal concentrations (F) of a xenobiotic absorbed
through the hand epithelium during the first week ofoccupational
exposure at 10 (A,B), 20 (C,D), 30 (E,F), and 40 (G,H) weeks of
gestation. Simulations with constant absorption through the hand
during pregnancy are illustrated bypanels onthe left. Simulations
withincreasingabsorptionthroughthe handduring pregnancy are
illustrated on the right.
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concurrent experimentation using in vivo and in vitro
systems; and development of expert systems for con-
sistent prediction ofhuman reproductive risk from an-
imal data.
At the present time, the most compelling need is the
development ofdatabases ofphysiological, pharmacok-
inetic, and metabolic parameters within and across spe-
cies during gestation and development. Once data are
available, itwillbepossible tobegintestingmechanism-
basedphysiologicalandpharmacokinetic modelsand ex-
pert systems forquantitative riskassessment. The data
base, alone and together with the physiological and
pharmacokinetic models, will also suggest in vivo and
in vitro experiments to validate the risk estimates and
reduce their uncertainty. Finally, the data base will be
areusable and continuously growingscientificresource.
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